More than 600,000 bottles of the blood pressure medication Ramipril have been recalled across the United States after safety concerns were identified. The recall was announced by the U.S. Food and Drug Administration (FDA) because some ingredients were sourced from an unapproved and uninspected manufacturing facility in India.

Ramipril is an ACE inhibitor commonly prescribed to treat high blood pressure and reduce the risk of heart attack, stroke, and kidney damage. More than 2.4 million Americans rely on this medication each year, making the recall important for both patients and healthcare providers.

The recalled products were manufactured by Lupin Pharmaceuticals. They include ramipril capsules in 2.5 mg, 5 mg, and 10 mg strengths. Bottles containing 90, 100, or 500 capsules with expiration dates through July 2026 are part of the recall and were distributed widely through pharmacies and hospitals.

According to the FDA, the action was taken as a precaution because ingredients from uninspected facilities may not meet required safety and quality standards. So far, officials say no adverse health events linked to the recalled medication have been reported.

Patients are strongly advised not to stop taking ramipril suddenly, since doing so could cause dangerous increases in blood pressure. Instead, they should check their medication labels and contact a pharmacist or healthcare provider if their bottle matches the recalled batches.

Pharmacies may provide replacement medication, and doctors may prescribe alternative ACE inhibitors such as Lisinopril or Enalapril if necessary. Any unusual symptoms should be reported to a healthcare provider and to the FDA’s MedWatch program.

The recall also highlights the importance of strict monitoring in the global pharmaceutical supply chain, where medication ingredients often come from several countries. Regulators emphasize that recalls like this are precautionary measures meant to protect patients and ensure medications remain safe and effective.